MIRM
NASD Mirum Pharmaceuticals, Inc.$83.14 ↑ +0.21 (+0.25%) Trading Up from the previous close of $82.93
- YTD change
- +5.25%
- vs 20-day SMA
- -10.40%
- vs 200-day SMA
- -15.38%
Price ranges
Price & Performance
-13.31 (-13.83%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 36.0% away from all-time highs of $130.00
- MIRM is up 5% since the beginning of the year
- MIRM is up 14% over the past 12 months
- MIRM is down 17% over the past 1 month
- 12% of all MIRM investors are betting against MIRM
MIRM reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +14.3%.
- Previous minute
- +$0.00
- Last hour
- +$0.21
- Last 5 days
- -7.31%
- vs 8-day SMA
- -4.47%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
